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Background: The global financial crisis threatens global health, particularly exacerbating diseases of inequality, e.g. 
HIV/AIDS, and diseases of poverty, e.g. tuberculosis. The aim of this paper is to reconsider established practices and 
policies for HIV and tuberculosis epidemic control, aiming at delivering better results and value for money. This may be 
achieved by promoting greater integration of HIV and tuberculosis control programme activities within a strengthened 
health system.
Discussion: HIV and tuberculosis share many similarities in terms of their disease burden and the recommended 
stratagems for their control. HIV and tuberculosis programmes implement similar sorts of control activities, e.g. case 
finding and treatment, which depend for success on generic health system issues, including vital registration, drug 
procurement and supply, laboratory network, human resources, and financing. However, the current health system 
approach to HIV and tuberculosis control often involves separate specialised services. Despite some recent progress, 
collaboration between the programmes remains inadequate, progress in obtaining synergies has been slow, and 
results remain far below those needed to achieve universal access to key interventions. A fundamental re-think of the 
current strategic approach involves promoting integrated delivery of HIV and tuberculosis programme activities as part 
of strengthened general health services: epidemiological surveillance, programme monitoring and evaluation, 
community awareness of health-seeking behavior, risk behaviour modification, infection control, treatment scale-up 
(first-line treatment regimens), drug-resistance surveillance, containing and countering drug-resistance (second-line 
treatment regimens), research and development, global advocacy and global partnership. Health agencies should 
review policies and progress in HIV and tuberculosis epidemic control, learn mutual lessons for policy development 
and scaling up interventions, and identify ways of joint planning and joint funding of integrated delivery as part of 
strengthened health systems.
Summary: As both a danger and an opportunity, the global financial crisis may entail disaster or recovery for global 
health sector efforts for HIV and tuberculosis epidemic control. Review of policies and progress in control paves the 
way for identification of synergies between the two programmes, within strengthened health services. The silver lining 
in the global economic crisis could be better control of the HIV and tuberculosis epidemics, better overall health 
system performance and outcomes, and better value for money.
Background
The silver lining in the cloud of the global economic crisis
is the enforced fundamental re-think of the status quo,
not only in the financial world, but also in many other
spheres affected by the crisis. "The crisis is too good to
waste" - this means for global health it is opportune to
reconsider established practices and policies with the aim
of improving health system performance and delivering
better results and value for money. This will not only help
during the economic downturn to maintain the momen-
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pare the ground for even greater health gains when the
global economy recovers. The global financial crisis
threatens global health, particularly exacerbating diseases
of inequality such as HIV/AIDS and diseases of poverty
such as tuberculosis. The approaches to HIV and tuber-
culosis epidemic control are ripe for a re-think. In this
paper we look for a possible silver lining in the global eco-
nomic crisis regarding health sector efforts for the con-
trol of HIV and tuberculosis, which are both among the
leading infectious causes of illness and death worldwide
[1].
HIV and tuberculosis share many similarities in epi-
demic characteristics and challenges in mounting an
effective health sector response [2]. Despite also consid-
erable overlap in epidemiology [2], the status quo is that
not enough has been made of the opportunities for
mutual learning and interaction between the respective
control programmes. Re-thinking the status quo can help
both programmes in two ways: firstly, to learn from each
other's experiences with the aim of expediting implemen-
tation of their respective stratagems for epidemic control,
and secondly, to improve collaboration and advance
progress in areas of mutual concern. As part of efforts to
strengthen overall health system performance, maximiz-
ing synergies and decreasing inefficiencies in the
approaches to HIV and tuberculosis epidemic control can
generate substantial health gains.
The aim of this paper is to re-think established prac-
tices and policies for HIV and tuberculosis epidemic con-
trol. First there is a comparison between HIV and
tuberculosis, showing the important differences, similari-
ties and overlap between these epidemics. This then
enables identification of the similarities in the main strat-
agems for HIV and tuberculosis epidemic control. Review
of the current status of the HIV and tuberculosis epidem-
ics and of implementation of control measures leads to
the conclusion that these epidemics are far from under
control, necessitating a re-think of established practices
and policies. Based on the similarities between control
stratagems, approaches are proposed for better HIV and
tuberculosis epidemic control. The opportunities identi-
fied for greater synergies between these programmes and
the health system could deliver better results and value
for money. Although the main focus is on developing
countries, which bear the brunt of both epidemics and
have the least resources for the health sector response,
lessons may also be applicable to developed countries.
Discussion
HIV and tuberculosis - differences, similarities and overlap
HIV is very new and infection is as yet incurable; tuber-
culosis very old and has been curable with drugs for the
past 60 years. The HIV epidemic arose in the twentieth
century following the cross-species transfer of simian
immunodeficiency viruses from primates to humans [3].
HIV currently infects 33 million out of the global popula-
tion of 6 billion people, i.e. 0.5% of the world's population
[4]. HIV infection is lifelong, and fatal if untreated. The
virulence of HIV as a new human pathogen mitigates
against its success and its further spread may depend on
its evolution with selection of less virulent strains. In con-
trast to the modernity of HIV, the Mycobacterium tuber-
culosis complex clonal group responsible for causing
tuberculosis has co-evolved with humanity over the past
three million years - our remote early hominid ancestors
may have suffered from tuberculosis [5]. Once infected
with M. tuberculosis, a person remains infected for many
years, probably for life. The vast majority (90%) of people
who are infected with M. tuberculosis do not develop
tuberculosis [6]. The risk of tuberculosis following M.
tuberculosis infection is determined mainly by the indi-
vidual's immune status (and hence HIV infection is a
potent risk factor for tuberculosis). Even in the absence of
treatment, self-cure occurs in three out of ten patients
with tuberculosis (without HIV infection) [7]. The suc-
cess of M. tuberculosis as a human pathogen, infecting
about one-third of the world's population, reflects the
extremely long and close relationship it has enjoyed with
humanity [8].
The nature of the interaction between the two human
pathogens, with a close relationship between HIV and
tuberculosis, is a consequence of the fact that HIV is a
very new and M. tuberculosis a very old pathogen. HIV
and M. tuberculosis share several similarities in their
interaction with the human host. They are both life-long
infections, with a long and variable latent period between
infection and onset of disease - in the case of HIV, about
two years in Africa [9] (longer in developed countries)
and in the case of M. tuberculosis, usually less than five
years [10]. In both cases, the outlook for the infected indi-
vidual is worse the later the detection of disease and the
start of treatment [11,12]. The annual global toll of deaths
from HIV and from tuberculosis is similar - in 2007 there
were 1.5 million deaths from HIV [4] (excluding those
with tuberculosis), 1.3 million deaths from tuberculosis
(among HIV-negative people) [13], and 0.5 million deaths
among people with HIV and tuberculosis [13]. The
worldwide epidemics of HIV and tuberculosis are both
out of control, with HIV still infecting people faster than
the pace of antiretroviral treatment roll-out [4] and the
absolute number of annual tuberculosis cases still
increasing [13].
There is a considerable overlap between those infected
with HIV and those infected with M. tuberculosis, espe-
cially in sub-Saharan Africa [14], with tuberculosis a lead-
ing cause of death among people with HIV infection [14].
Tuberculosis and HIV control programmes clearly have
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treatment of HIV/AIDS should be components of tuber-
culosis control, and tuberculosis care and prevention
should be priorities in the management of HIV/AIDS
[15,16]. Despite recognition of the potential benefits of
collaboration between tuberculosis programmes and
HIV/AIDS programmes they have often continued to
pursue separate courses [17]. They can no longer afford
to do so in an era of global economic crisis which
demands maximum cost efficiencies. The exigencies of
the global economic crisis provide an impetus for HIV
programmes and tuberculosis programmes together to
take stock of their activities and progress in epidemic
control. They need to consider not only how to improve
collaboration aimed at advancing progress in the areas of
mutual concern, but also how to learn from each other's
experiences with the aim of advancing progress in imple-
menting their respective main stratagems for epidemic
control.
Stratagems for HIV and tuberculosis epidemic control
The principle of infectious disease epidemic control is to
reduce the average number of people infected by each
infectious case so that the case reproduction number is
less than one. This results in declining incidence of infec-
tion. The main stratagems for HIV and tuberculosis epi-
demic control include: prevention of primary infection,
modification of risk factors for infection, drug prophy-
laxis, decreased transmission by treatment of infected
individuals (treatment as prevention), and vaccination to
prevent progression from infection to disease. The
emphasis has been on different stratagems for HIV and
for tuberculosis epidemic control, with decreased trans-
mission by treatment of infected individuals (treatment
as prevention) gaining attention recently for HIV,
whereas this has been the mainstay of tuberculosis con-
trol for the past 60 years.
The emphasis in HIV control has until recently mainly
been on promoting behavioural modifications aimed at
decreasing the risk of primary infection [18]. In revolutio-
nising the care of people with HIV, antiretroviral therapy
(ART) has opened the door to treatment as prevention.
The benefits of early ART initiation are not only
improved individual patient outcomes but also reduced
infectiousness and therefore decreased HIV transmission
[19]. How best to use ART for prevention has emerged as
the most pressing question that faces HIV/AIDS science
[20]. Could universal voluntary testing with immediate
ART be a strategy for elimination of HIV transmission? A
mathematical model shows that this strategy could
greatly accelerate the transition from the present endemic
phase, in which most adults with HIV infection are not
on ART, to an elimination phase, in which most are on
ART, within 5 years [21]. There is an urgent need for
research to establish the feasibility of this approach and
validate the modeling results.
Removal of tuberculosis patients from their homes for
isolation in sanatoria may have played a role in decreasing
M. tuberculosis transmission in the pre-chemotherapy
era. However the development of specific anti-tuberculo-
sis chemotherapy 60 years ago raised the prospect of
reducing transmission risk through decreased infectious-
ness of the index cases [22]. This can be achieved by
prompt diagnosis and effective treatment, which lie at the
heart of modern approaches to tuberculosis control [23].
With proper treatment, a person with infectious tubercu-
losis very quickly becomes non-infectious - probably
most often in less than two weeks - and so can no longer
transmit infection to others [24].
Shortening the period of infectivity can maximize the
impact of ART and of antituberculosis chemotherapy on
transmission of HIV and M. tuberculosis respectively. In
the case of HIV, substantial transmission occurs while the
infected person is asymptomatic, so shortening the
period of infectivity may well require regular testing of
asymptomatic people for HIV infection, and testing of
people after an at-risk exposure, as well as prompt diag-
nosis and effective treatment of people when they present
with symptoms of HIV-related disease. In the case of
tuberculosis, transmission occurs from patients with pul-
monary tuberculosis when they are symptomatic with
cough, so early diagnosis requires patient access to qual-
ity health services providing rapid and reliable diagnosis.
In both cases, promotion of community awareness is nec-
essary for effective health-seeking behaviour, so that peo-
ple understand and accept the need for testing as early as
possible to maximize the possibility of effective action to
decrease transmission.
The specific interventions to address HIV and tubercu-
losis can be grouped under the main stratagems for epi-
demic control (prevention of primary infection,
modification of risk factors for infection, drug prophy-
laxis, decreased transmission by treatment of infected
individuals, and vaccination to prevent progression from
infection to disease) (Table 1) [25-45].
Current status of HIV and tuberculosis epidemics and of 
control measures
Assessment of the current status of the HIV and tubercu-
losis epidemics indicates that these epidemics are far
from under control (Table 2) [2,4,13].
Although there has been considerable progress in
global implementation of measures for HIV and tubercu-
losis epidemic control, there is still a long way to go
before achieving universal access for all to HIV and
tuberculosis diagnosis and treatment (Table 3) [13,46-50].
Regarding activities requiring collaboration between
HIV and tuberculosis programmes ("collaborative TB/
Maher BMC Public Health 2010, 10:394
http://www.biomedcentral.com/1471-2458/10/394
Page 4 of 11
Table 1: Specific interventions to address HIV and tuberculosis grouped under the main stratagems for epidemic control
Stratagem HIV Tuberculosis
Prevention of primary infection
behavioural modification decreased risk exposure, e.g. safe sex and 
decreased sex partners [25] and safe injecting 
drug use [26]
education, e.g. cough hygiene [27]
environmental modification decreased risk of occupational exposure 
through safe handling and disposal of sharps
environmental measures to decrease 
nosocomial transmission [27,28] (particularly 
important where HIV prevalence is high)
protect site of infection vaginal microbicides (under evaluation) [29] face masks (NN95 specification) [27]
Modification of risk factors for infection
promote decreased substance abuse decreased alcohol [30] and drugs [30] decreased alcohol [31] and smoking [32]
detect and treat conditions associated with 
increased risk
treatment of sexually transmitted infections [33] detection and management of diabetes [34]
modify personal biological characteristic male circumcision [35]
Drug prophylaxis
pre-exposure pre-exposure prophylaxis (under 
evaluation) [36]
isoniazid preventive treatment for infants 
born to mothers with tuberculosis [37]
pre- and post-exposure prevention of mother to child transmission [38]
post-exposure post-exposure prophylaxis [39] isoniazid preventive treatment for people 
with latent M. tuberculosis infection or 
for people at high risk of recurrent 
tuberculosis [40]
Decreased transmission by treatment of infected individuals (treatment as prevention) [41]
prompt diagnosis and effective treatment of 
people with symptomatic HIV-related 
disease [42]
prompt diagnosis and effective treatment of 
people with symptomatic pulmonary 
disease [23]
proposal for prompt diagnosis among 
asymptomatic individuals either through an 
individual seeking a test for HIV after an at-risk 
exposure or through regular universal 
testing [43]
efforts aimed at decreasing diagnostic delay 
through community education, improved 
access to care, and improved quality of 
clinical care [44]
Vaccination to prevent progression from infection to disease
no vaccine yet available Bacille Calmette-Guerin (BCG) vaccination [45]
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mentation of these interventions is far below the need
[46], and far below the targets for 2015 set out in the
"Global Plan to Stop TB" (Table 4) [51].
Re-thinking established practices and policies for effective 
epidemic control
A key question arises from consideration of the current
status of the HIV and tuberculosis epidemics and of
implementation of epidemic control measures: what is
the most effective and efficient health system approach to
ensuring more widespread and sustainable access to
interventions for HIV and for tuberculosis epidemic con-
trol? One approach is to continue with more of the same,
i.e. specialised services for HIV and for tuberculosis with
what may in some ways be regarded as a third pro-
gramme of TB/HIV collaboration. Alternatively, a funda-
mental re-think of the current strategic approach involves
promoting integrated services for HIV and tuberculosis
which are part of strengthened general health services.
The contrasting experiences of global HIV and tuber-
culosis control provide some insights in answering this
question. Accompanying the development of antituber-
culosis chemotherapy regimens in the 1960s and 1970s,
the move away from the previous policy of specialised
tuberculosis diagnosis and treatment services to integra-
tion into primary care in most countries, played a critical
role in facilitating widespread access [23]. After integrat-
ing tuberculosis services with general health services, and
decentralizing with community support [52], the bottle-
neck in expanding access to tuberculosis diagnosis and
treatment is the quality of the general health services.
This was recognised in the early years of this decade by
the second ad hoc committee on the tuberculosis epi-
demic: "progress in tuberculosis control... depends on
actions which are beyond the specifics of tuberculosis
control" [53]. Although the committee's recommenda-
tions to stakeholders in tuberculosis control included to
"strengthen health systems, particularly primary care
delivery", progress in harnessing tuberculosis control
efforts to the cause of health system strengthening has
been slow and the health system bottleneck remains.
Regarding HIV programmes, the process of ensuring
widespread and sustainable access has largely been
through specialised services, rather than decentralized,
integrated services. The picture of service provision for
HIV in many developing countries is a mix of specialised
services and integrated services, but the process of inte-
gration is generally at an earlier stage than with tubercu-
losis programmes. The UNAIDS policy advice that
"greater attention must be paid to integrating HIV ser-
vices into primary health care as part of managing
chronic diseases" [46] is yet to be widely translated into
action.
Given the different stages of development of integrated
services for HIV and for tuberculosis programmes, the
picture for areas of collaborative activity between HIV
and tuberculosis programmes is predictably complicated.
Although in the early years of this decade, the World
Health Organization developed a global policy on HIV
and tuberculosis programme collaboration representing
an integrationist approach, with HIV and tuberculosis
programme activities integrated into general health ser-
vices [54], this was soon replaced by a revised approach,
with emphasis on collaboration between HIV and tuber-
culosis programmes and little reference to the need for
integration with general health services [55]. This led to
the establishment of what may be considered a third ver-
tical programme on "TB/HIV" [56] alongside the existing
HIV and tuberculosis programmes. The slow progress in
expanding access to interventions of mutual concern to
HIV and tuberculosis programmes may be attributable at
least in part to the policy failure to promote integrated
services (taking into consideration the need for attention
to infection control) within strengthened general health
services.
Many of the types of activities for epidemic control
undertaken by HIV and tuberculosis programmes are the
same but are often undertaken separately e.g. epidemio-
logical surveillance, programme monitoring and evalua-
Table 2: Estimates of key selected indicators of current status of HIV and tuberculosis epidemics
Indicator HIV Tuberculosis
annual incident cases (all) 2·5 million incident infections in 2007 [4] 9.3 million incident cases in 2007 [13]
annual deaths 2.1 million [2] (includes 0.5 million people 
with tuberculosis and HIV co-infection) [13]
1.3 million (excludes 0.5 million people 
co-infected with HIV) [13]
annual incident cases of drug-resistant 
strains
Global estimate not available. 0.5 million in 2007 [13]
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Table 3: Key selected indicators of progress in global implementation of measures for HIV and tuberculosis epidemic 
control
Measure HIV Tuberculosis
diagnosis (proportion diagnosed among all 
with HIV or tuberculosis)
No global figure available in UNAIDS report 
[46]. Based on data from 12 low and middle-
income countries, 20% of people with HIV 
infection know their status [46].
5.5 million cases diagnosed and treated in 
2007 under programmes in line with global 
strategy to Stop TB/9.3 million estimated 
incident cases (59%) [13].
provision of first-line treatment (proportion 
receiving treatment among all those needing 
it)
ART 4 million/9.5 million at the end of 2007 
[46] (42%)
treatment success rate No global documentation of overall rate of 
successful treatment outcome ("highly 
heterogeneous monitoring systems and the 
use of non-standardised definitions across 
programmes create additional hurdles for 
accurately measuring the success of 
programmes") [46]
85% global treatment success rate in 2006 for 
patients with sputum smear-positive 
pulmonary tuberculosis treated in line with 
the global strategy to Stop TB [13].
Average retention in ART treatment 
programmes in sub-Saharan Africa was 75% 
after one year and 62% after two years [47].
75% treatment success rate (patients with 
sputum smear-positive pulmonary 
tuberculosis) in the WHO Africa region in 
2006 [13].
drug-resistance surveillance 25 countries "were planning or 
implementing" WHO's global strategy for 
prevention and assessment of HIV drug 
resistance [48]. Seven countries have 
reported results [48].
Data from 90,726 patients in 83 countries and 
territories between 2002 and 2007 [49].
diagnosis of drug-resistant cases No global figure available from UNAIDS 
report [46]. In nine countries reporting results 
from surveillance of transmitted HIV drug 
resistance from areas where ART was first 
used in the country, the prevalence of 
transmitted resistance was less than 5% [46].
30,000 cases of multidrug-resistance among 
people with smear-positive pulmonary 
tuberculosis diagnosed in 2007/353,000 
estimated total worldwide (8.5%) [13].
provision of second-line treatment 
(proportion receiving treatment among all 
those needing it)
Results of a survey by national HIV 
programmes in 41 countries showed that 3% 
of people receiving ART were on second-line 
regimens [50]. The estimated number of 
people needing second-line ART is unknown.
3,681 cases of multidrug-resistance among 
people with smear-positive pulmonary 
tuberculosis known to be treated in 
2007 according to international guidelines/
353,000 estimated total worldwide 
cases (1%) [13].
treatment success rate (among people 
treated for drug-resistant HIV)
No global figure available from UNAIDS 
report [46].
Although "the size of most country cohorts in 
2004 was too small to allow any useful 
analysis", treatment success rate ranged 
between about 50-70% for cohorts of 
patients treated according to international 
guidelines [13].
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risk behaviour modification, infection control, treatment
scale-up (first-line treatment regimens), drug-resistance
surveillance, containing and countering drug-resistance
(second-line treatment regimens), research and develop-
ment for new diagnostics, drugs and vaccines, global
advocacy and global partnership. Implementation of
these activities by the two programmes depends on the
same health system issues, including vital registration,
drug procurement and supply, laboratory network,
human resources, financing, and health sector reform.
Identifying such activities where joint efforts for HIV and
for tuberculosis epidemic control can strengthen health
services would help to maximize synergies (Table 5)
[4,11-13,27,44,46,49,51,52,57,58]. The global economic
crisis highlights the urgent need for international and
national health organizations to review systematically the
activities of HIV and tuberculosis programmes to identify
opportunities for greater synergies between these indi-
vidual health programmes and the health system and to
deliver better results and value for money.
There are recent signs of an increasingly favourable
global policy environment for this approach. Last year
WHO launched the effort to "Maximize positive syner-
gies between global health initiatives and health systems"
[59]. Dr Carissa Etienne, assistant Director-General,
WHO, has commented that "The financial crisis poses
some fundamental questions about the way the interna-
tional community uses its resources. And the response is
that while we clearly need more funds for health, we also
need to identify opportunities to deliver better results
and value for money...promoting greater synergies
between health systems and individual health pro-
grammes are key to making this happen" [60]. Suggested
reforms in international health financing include incor-
porating the Global Fund to Fight AIDS, Tuberculosis
and Malaria and the Global Alliance on Vaccines and
Immunisations in a global fund for all the health Millen-
nium Development Goals, with a mandate to address pri-
ority health problems and key bottlenecks in health
systems [61].
Conclusion
The global financial crisis threatens global health [62], in
particular exacerbating diseases of inequality such as
HIV/AIDS [63] and diseases of poverty such as tubercu-
losis [64]. The benefits of collaboration between those
concerned with HIV and tuberculosis epidemic control
have been pointed out for a long time [65]. However,
despite some recent progress, collaboration remains
inadequate, progress in obtaining synergies has been
slow, and results remain far below those needed to
achieve the goal of universal access to key interventions.
"Crisis" is a medical metaphor derived from the concept
which probably predates Hippocrates of the turning point
of a disease - the moment after which a patient either
recovered or died. As both a danger and an opportunity,
the global financial crisis may entail disaster or recovery
for global health sector efforts for HIV and tuberculosis
epidemic control. International health agencies should
review policies and progress in epidemic control of HIV
and tuberculosis, with the aim of identifying synergies:
learning mutual lessons for policy development and for
scaling up implementation of interventions and identify-
ing ways of joint planning and joint funding of integrated
services as part of strengthened health systems.
Although the global financial crisis poses a danger of
increased funding gaps for HIV and tuberculosis epi-
demic control programmes, it also represents an oppor-
tunity to re-think established practices and policies, with
the aim of delivering better results through greater health
system synergies with increased cost-effectiveness. The
silver lining in the global economic crisis could be better
control of the HIV and tuberculosis epidemics, better
overall health system performance and outcomes, and
better value for money.
Summary
• The global financial crisis represents both a danger 
and an opportunity for global health sector efforts for 
HIV and tuberculosis epidemic control.
• HIV and tuberculosis share many similarities in 
terms of their disease burden and the stratagems for 
epidemic control.
Table 4: Indicators of progress in implementation of 
collaborative TB/HIV interventions
intervention number of people 
accessing intervention 
in 2007
screening for tuberculosis 
among people with HIV
300,000/13 million target in 
Africa (2.3%) [13]
testing for HIV among 
notified tuberculosis cases
500,000/900,000 target in 
Africa (55.6%) [13]
provision of isoniazid 
preventive therapy to people 
living with HIV
27,000/33 million people 
living with HIV worldwide 
(0.1%) [46]
TB infection control in health 
and other congregate 
facilities
no quantitative measure 
("progress in implementing 
infection control 
interventions has been very 
slow" [46])
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integrated into a strengthened health system
Programme activity Challenge Example of HIV and 
tuberculosis programme 
collaboration
Consequence for strengthened 
health system
Programme monitoring and 
evaluation
Difficulty in measurement of the 
success of HIV treatment 
programmes because of highly 
heterogeneous monitoring 
systems and use of non-
standardised definitions across 
programmes [46]
Joint contribution to 
development of standard 
measures for monitoring success 
of treatment, e.g. ART for HIV 
infection, learning from 
experience of standard outcomes 
in global tuberculosis control [44]
Better global documentation of 
overall rate of successful outcome 
of treatment of HIV/AIDS a priority 
disease of poverty
Programme monitoring and 
evaluation
Lack of a vital registration system 
in many of the countries most 
badly affected by HIV or 
tuberculosis (only five countries in 
Africa have vital registration 
systems covering more than 25% 
of the population) [57]
Joint support of efforts to develop 
national vital registration systems
Improvements in coverage and 
quality of vital registration 
systems would be of considerable 
benefit for better data on deaths 
of people with priority diseases of 
poverty, e.g. HIV and tuberculosis
Infection control in health and 
other congregate facilities
Lack of quantitative measure of 
implementation of measures for 
HIV infection control and slow 
progress in implementing TB 
infection control interventions [46]
Joint contribution to 
development and 
implementation of effective 
health system policies for 
infection control in health and 
other congregate facilities
Strengthened ability of health 
system to protect patients from 
nosocomial infection
Raising community awareness of 
health-seeking behavior
Late presentation during disease 
progression of patients with HIV 
[11] and patients with 
tuberculosis [12]
Joint development and 
implementation of 
comprehensive communication 
measures aimed at raising 
community awareness of the 
importance of seeking health care 
earlier in the course of 
progression of priority diseases, 
e.g. HIV and tuberculosis
Better outcomes of treatment of 
patients presenting earlier in the 
course of disease, with health 
system efficiency savings
Risk behavior modification High continued levels of 
behaviour involving personal risk, 
e.g. unsafe sex [4] as a risk for HIV 
infection, and lack of cough 
hygiene as a risk for transmission 
of tuberculosis [27]
Joint contribution to 
comprehensive health education 
aimed at promoting healthy 
behavior and decreasing risk of 
HIV and tuberculosis
Improved health system 
approach to behavior 
modification regarding risk of HIV 
and tuberculosis among a wide 
range of diseases
Treatment scale-up (first-line 
treatment regimens)
Inadequate access to effective 
treatment of HIV infection [46] 
and tuberculosis [13]
Joint contribution to 
development and 
implementation of health system 
policies for decentralized 
provision of treatment of priority 
diseases, e.g. ART for HIV/AIDS, 
based on experiences of 
decentralised treatment of 
tuberculosis [52]
Faster progress towards goal of 
universal access to key 
interventions for control of 
priority diseases of poverty
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and tuberculosis remains inadequate, progress in 
obtaining synergies has been slow, and results remain 
far below those needed to achieve the goal of univer-
sal access to key interventions.
• International and national health agencies should 
review policies and progress in epidemic control of 
HIV and tuberculosis, with the aim of identifying syn-
ergies: learning mutual lessons for policy develop-
ment and for scaling up implementation of 
interventions and identifying ways of joint planning 
and joint funding of integrated services as part of 
strengthened health systems.
• The silver lining in the global economic crisis could 
be better control of the HIV and tuberculosis epidem-
ics, better overall health system performance and out-
comes, and better value for money.
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Drug-resistance surveillance Despite recent progress, 
insufficient laboratory capacity in 
countries most badly affected by 
HIV and by tuberculosis for 
surveillance of resistance to 
antiretroviral [46] and 
antituberculosis [13] drugs
Joint support of development of 
national and international 
capacity for drug-resistance 
surveillance, including resistance 
to antiretroviral and 
antituberculosis drugs
Improved health system capacity 
for drug-resistance surveillance, 
including resistance to 
antiretroviral and antituberculosis 
drugs
Containing and countering drug-
resistance (including rational use 
of second-line treatment 
regimens)
Failure to contain the spread of 
drug-resistance [46,49]
Supporting health system 
capacity to contain drug-
resistance, by learning mutual 
lessons from experiences in HIV 
and tuberculosis treatment
Improved health system capacity 
to contain resistance to drugs 
used in treatment of a wide range 
of diseases
Research and development for 
new diagnostics, drugs and 
vaccines
Inadequate development of new 
diagnostics, drugs and vaccines, 
especially for tuberculosis [51]
Joint support of advocacy for 
increased funding, and for 
development of platforms, for 
research and development
More efficient and effective health 
system contribution to 
development of new 
technologies for disease control
Global advocacy for resources Competition between advocates 
promoting resource mobilisation 
for different diseases
Joint advocacy for funding of 
strong health systems which are 
able to respond effectively across 
a range of disease priorities and 
benefit from synergies of 
approaches to different diseases
More effective health system 
based on funding of disease 
control commensurate with the 
burden of disease
Global partnership Failure to maximize synergies and 
avoid duplication and dispersion 
of effort among partners
Joint support of global 
partnerships which embrace joint 
HIV and tuberculosis issues (e.g. 
Global Fund for AIDS, 
Tuberculosis and Malaria) and of 
more cohesive global HIV 
partnerships, learning from 
lessons of the global Stop TB 
Partnership [58]
More effective and efficient roles 
played by partners in global 
health partnerships and in global 
HIV and tuberculosis partnerships
Table 5: Examples of programme activities where joint efforts for HIV and for tuberculosis epidemic control can be better 
integrated into a strengthened health system (Continued)
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